BEYONDSPRING (BYSI) Files 8-K on Nasdaq Listing Compliance Issue
The clinical-stage biotech filed an Item 3.01 disclosure covering a delisting notice or failure to meet a continued listing standard.
BeyondSpring (BYSI) filed a current report on Form 8-K with the Securities and Exchange Commission disclosing an item under Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The filing was submitted on 18 September 2026 and carries an event date of 17 September 2026.
